Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.